Drug General Information
Drug ID	D0EO2C
Former ID	DIB012871
Drug Name	LY-2881835
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 1	[523492]
Company	Eli Lilly & Co
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	GPR40	Target Info	Modulator	[544438]
KEGG Pathway	Insulin secretion
Reactome	G alpha (q) signalling events
	Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
WikiPathways	GPCRs, Class A Rhodopsin-like
	Incretin Synthesis, Secretion, and Inactivation
	Gastrin-CREB signalling pathway via PKC and MAPK
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 523492	ClinicalTrials.gov (NCT01358981) A Study of LY2881835 in Healthy People and People With Diabetes. U.S. National Institutes of Health.
Ref 544438	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.